Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsThe authors provide insights into the mode of action of HMA, mechanisms of resistance to this treatment, and strategies to overcome HMA resistance including next-generation HMA and HMA-based combination therapies.
[Leukemia]
6445218 AUZWLMDV items 1 apa 0 default asc 1 162031 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-ace313c33d10cbc27d729ac5fa8209d2%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22AUZWLMDV%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Stomper%20et%20al.%22%2C%22parsedDate%22%3A%222021-05-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EStomper%2C%20J.%2C%20Rotondo%2C%20J.%20C.%2C%20Greve%2C%20G.%2C%20%26amp%3B%20L%26%23xFC%3Bbbert%2C%20M.%20%282021%29.%20Hypomethylating%20agents%20%28HMA%29%20for%20the%20treatment%20of%20acute%20myeloid%20leukemia%20and%20myelodysplastic%20syndromes%3A%20mechanisms%20of%20resistance%20and%20novel%20HMA-based%20therapies.%20%3Ci%3ELeukemia%3C%5C%2Fi%3E%2C%201%26%23x2013%3B17.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-021-01218-0%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-021-01218-0%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3DAUZWLMDV%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hypomethylating%20agents%20%28HMA%29%20for%20the%20treatment%20of%20acute%20myeloid%20leukemia%20and%20myelodysplastic%20syndromes%3A%20mechanisms%20of%20resistance%20and%20novel%20HMA-based%20therapies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Stomper%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20Charles%22%2C%22lastName%22%3A%22Rotondo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriele%22%2C%22lastName%22%3A%22Greve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22L%5Cu00fcbbert%22%7D%5D%2C%22abstractNote%22%3A%22Aberrant%20DNA%20methylation%20plays%20a%20pivotal%20role%20in%20tumor%20development%20and%20progression.%20DNA%20hypomethylating%20agents%20%28HMA%29%20constitute%20a%20class%20of%20drugs%20which%20are%20able%20to%20reverse%20DNA%20methylation%2C%20thereby%20triggering%20the%20re-programming%20of%20tumor%20cells.%20The%20first-generation%20HMA%20azacitidine%20and%20decitabine%20have%20now%20been%20in%20standard%20clinical%20use%20for%20some%20time%2C%20offering%20a%20valuable%20alternative%20to%20previous%20treatments%20in%20acute%20myeloid%20leukemia%20and%20myelodysplastic%20syndromes%2C%20so%20far%20particularly%20in%20older%2C%20medically%20non-fit%20patients.%20However%2C%20the%20longer%20we%20use%20these%20drugs%2C%20the%20more%20we%20are%20confronted%20with%20the%20%28almost%20inevitable%29%20development%20of%20resistance.%20This%20review%20provides%20insights%20into%20the%20mode%20of%20action%20of%20HMA%2C%20mechanisms%20of%20resistance%20to%20this%20treatment%2C%20and%20strategies%20to%20overcome%20HMA%20resistance%20including%20next-generation%20HMA%20and%20HMA-based%20combination%20therapies.%22%2C%22date%22%3A%222021-05-06%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41375-021-01218-0%22%2C%22ISSN%22%3A%221476-5551%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41375-021-01218-0%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-05-08T06%3A16%3A56Z%22%7D%7D%5D%7D
Stomper, J., Rotondo, J. C., Greve, G., & Lübbert, M. (2021). Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia, 1–17. https://doi.org/10.1038/s41375-021-01218-0 Cite
